| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca |
DermAtOmics-II, NCT06366932: Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models |
|
|
| Recruiting | 4 | 150 | Europe | Second-line systemic treatment, Dupilumab, Tralokinumab, Upadacitinib, Baricitinib, Abrocitinib, Folllow-up of second-line systemic treatment already started | Instituto de Investigación Hospital Universitario La Paz | Atopic Dermatitis | 09/25 | 09/25 | | |
2013-005615-27: A Phase 3 study to evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents with asthma that is not controlled. |
|
|
| Ongoing | 3 | 78 | Europe | Tralokinumab, CAT-354, | AstraZeneca AB, AstraZeneca AB | Asthma | | | | |
2020-005976-36: Trial to investigate which atopic dermatitis patients will respond to the biologic therapy tralokinumab |
|
|
| Not yet recruiting | 3 | 42 | Europe | Tralokinumab | Karolinska Universitetssjukhuset, Dermagnostix R&D | Atopic Dermatitis, Atopic Dermatitis, Diseases [C] - Immune System Diseases [C20] | | | | |
INJECZTRA, NCT05194540: Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis |
|
|
| Completed | 3 | 136 | US | Tralokinumab | LEO Pharma | Atopic Dermatitis | 06/23 | 06/23 | | |
TRAPEDS 2, NCT06311682: A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 195 | Canada, US | Tralokinumab + TCS, Placebo + TCS | LEO Pharma | Atopic Dermatitis | 03/26 | 04/28 | | |
| Completed | 3 | 1672 | Europe, Canada, Japan, US, RoW | Tralokinumab | LEO Pharma | Atopic Dermatitis | 07/24 | 07/24 | | |
|
|
|
|
ADHAND, NCT05958407: A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy |
|
|
| Recruiting | 3 | 402 | Europe, Canada, US, RoW | Tralokinumab, Placebo | LEO Pharma | Atopic Dermatitis, Atopic Hand Eczema | 11/26 | 03/27 | | |
TRALIS, NCT05378698: Effects of Tralokinumab in the Skin: an Immunologic and Molecular Investigation |
|
|
| Not yet recruiting | 2/3 | 25 | Europe | Application of Tralokinumab | University of Zurich, Hochgebirgsklinik Davos-Wolfgang | Atopic Dermatitis | 12/24 | 06/25 | | |
2019-000598-22: Effects of Tralokinumab treatment of atopic dermatitis on skin barrier function (TraSki) Die Auswirkung einer Tralokinumab-Behandlung auf die Hautbarrierefunktion bei Patienten mit moderater bis schwerer Neurodermitis (TraSki) |
|
|
| Not yet recruiting | 2 | 16 | Europe | Tralokinumab, Solution for injection in pre-filled syringe, Adtralza | University Hospital Schleswig Holstein, Represented by the Board of Directors which is represented by the chairman, LEO Pharma A/S | Patients with moderate to severe atopic dermatitis Patienten mit moderater bis schwerer Neurodermitis, Patients with moderate to severe atopic dermatitis Patienten mit moderater bis schwerer Neurodermitis, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
| Completed | 2 | 16 | Europe | Tralokinumab | Prof. Dr. Stephan Weidinger, LEO Pharma A/S | Atopic Dermatitis | 07/22 | 03/23 | | |
NCT05388760 / 2021-005573-12: Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1) |
|
|
| Active, not recruiting | 2 | 24 | Europe, RoW | Tralokinumab | LEO Pharma | Atopic Dermatitis | 10/23 | 04/26 | | |
NCT03358693: Molecular Signatures in Inflammatory Skin Disease |
|
|
| Recruiting | N/A | 300 | Europe | Ustekinumab, Infliximab, Secukinumab, Dupilumab, Brodalumab, Ixekizumab, Baricitinib, Abrocitinib, Upadacitinib, Tralokinumab | Prof. Dr. Stephan Weidinger | Atopic Dermatitis, Psoriasis | 12/27 | 12/28 | | |
PROTECT, NCT05938478: Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - |
|
|
| Recruiting | N/A | 900 | US | Tralokinumab, Adbry, Adtralza | University of California, San Diego, LEO Pharma, The Organization of Teratology Information Specialists | Atopic Dermatitis, Eczema | 11/34 | 09/35 | | |
| Not yet recruiting | N/A | 100 | Europe | | Nantes University Hospital, LEO Pharma | Atopic Dermatitis | 07/25 | 03/26 | | |
